^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunomodulator

    Related drugs:
    3d
    Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects (clinicaltrials.gov)
    P1, N=76, Completed, Athos Therapeutics Inc | Recruiting --> Completed
    Trial completion
    3d
    R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Rise Therapeutics LLC
    New P1 trial • Combination therapy • Checkpoint inhibition • Immune cell
    3d
    Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Williams Cancer Foundation | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    3d
    Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, Diwakar Davar | Suspended --> Active, not recruiting | N=36 --> 9 | Trial completion date: Jul 2030 --> Jul 2028
    Enrollment closed • Enrollment change • Trial completion date • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)
    4d
    Research on the metabolic regulation mechanism of Yangyin Qingfei decoction plus in severe pneumonia caused by Mycoplasma pneumoniae in mice. (PubMed, Front Pharmacol)
    The contents of chlorogenic acid, paeoniflorin, forsythrin A, forsythrin, and paeonol in YQDP were 3.480 ± 0.051, 3.255 ± 0.040, 3.612 ± 0.017, 1.757 ± 0.031, and 1.080 ± 0.007 mg/g respectively... A specific intervention effect of YQDP is observed in SMPP model mice. Through the PI3K/Akt/NF-κB signaling pathways, YQDP may have therapeutic benefits by regulating the body's metabolism of α-Linoleic acid, sphingolipids, glycerophospholipids, arachidonic acid, and the production of unsaturated fatty acids.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    chlorogenic acid
    4d
    Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Initiation date: Mar 2024 --> Sep 2024
    Trial initiation date
    |
    melphalan • fludarabine IV • thiotepa • Orca-T
    6d
    Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis (clinicaltrials.gov)
    P4, N=51, Completed, Beijing Stomatological Hospital, Capital Medical University | Not yet recruiting --> Completed
    Trial completion
    6d
    Low Dose Naltrexone for Pain in Patients With HIV (clinicaltrials.gov)
    P4, N=60, Recruiting, Emory University | Suspended --> Recruiting | Trial completion date: Mar 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
    Enrollment open • Trial completion date • Trial primary completion date
    6d
    Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis (clinicaltrials.gov)
    P1/2, N=54, Recruiting, COUR Pharmaceutical Development Company, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    9d
    Hypoglycemic Activity of Rice Resistant-Starch Metabolites: A Mechanistic Network Pharmacology and In Vitro Approach. (PubMed, Metabolites)
    After network pharmacology analysis, 11 core metabolites were identified, including linolenic acid, chenodeoxycholic acid, ursodeoxycholic acid, deoxycholic acid, lithocholic acid, lithocholylglycine, glycoursodeoxycholic acid, phenylalanine, norepinephrine, cholic acid, and L-glutamic acid, and 16 core targets were identified, including MAPK3, MAPK1, EGFR, ESR1, PRKCA, FYN, LCK, DLG4, ITGB1, IL6, PTPN11, RARA, NR3C1, PTPN6, PPARA, and ITGAV...In vitro hypoglycemic experiments further suggested that bile acids showed significant inhibitory effects on α-glucosidase and α-amylase, with CDCA and UDCA having the most prominent inhibitory effect. In summary, this study reveals a possible hypoglycemic pathway of RRS metabolites and provides new research perspectives to further explore the therapeutic mechanism of bile acids in T2DM.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • IL6 (Interleukin 6) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • MAPK1 (Mitogen-activated protein kinase 1) • PRKCA (Protein Kinase C Alpha) • DLG4 (Discs Large MAGUK Scaffold Protein 4) • ITGB1 (Integrin Subunit Beta 1) • MAPK3 (Mitogen-Activated Protein Kinase 3) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    10d
    Dusquetide for the Treatment of Behcet's Disease (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Soligenix
    New P2 trial
    11d
    Antidepressant effect of teriflunomide via oligodendrocyte protection in a mouse model. (PubMed, Heliyon)
    Additionally, TF treatment facilitated a reduction in the levels of apoptosis-related proteins while simultaneously augmenting the levels of Bcl2. Our findings indicate that TF administration effectively mitigates CORT-induced depression-like behaviors and reverses damage to oligodendrocytes and neurons in the hippocampus, suggesting TF as a promising candidate for depression.
    Preclinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • SYP (Synaptophysin)
    12d
    Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis" (clinicaltrials.gov)
    P=N/A, N=1332, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    12d
    Inhibiting Pink1/Parkin-mediated mitophagy enhances the anticancer effects of quercetin in hepatocellular carcinomaf. (PubMed, Biochem Biophys Res Commun)
    In vivo experiments using Hep3B xenograft models revealed that the combination of quercetin with the mitophagy inhibitor hydroxychloroquine or SIRT1 knockdown significantly enhanced the anticancer effects of quercetin, as evidenced by reduced tumor size and weight, increased necrosis and apoptosis, and decreased proliferation in tumor tissues. These findings suggest that quercetin-induced mitochondrial fusion and Pink1/Parkin-dependent mitophagy may negatively influence its anti-cancer effects in HCC. Targeting mitophagy may enhance the therapeutic potential of quercetin in HCC treatment.
    Journal
    |
    SIRT1 (Sirtuin 1) • MFN2 (Mitofusin 2) • PINK1 (PTEN Induced Kinase 1)
    |
    hydroxychloroquine
    14d
    Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov)
    P2, N=10, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Dec 2024 --> Jun 2024
    Trial primary completion date
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    14d
    Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, University of Florida | Initiation date: May 2024 --> Aug 2024
    Trial initiation date
    14d
    A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults (clinicaltrials.gov)
    P1, N=324, Completed, GlaxoSmithKline | Active, not recruiting --> Completed
    Trial completion
    17d
    A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Cellcolabs Clinical LTD. | N=12 --> 30 | Trial completion date: Sep 2024 --> Oct 2028 | Trial primary completion date: May 2024 --> Oct 2027
    Enrollment change • Trial completion date • Trial primary completion date • Stroma
    17d
    A Study to Evaluate Mesenchymal Stem Cell Product StromaForte's Effect on Cardiovascular Events (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Cellcolabs Clinical LTD. | N=30 --> 100 | Trial completion date: Jul 2024 --> Oct 2029 | Trial primary completion date: Apr 2024 --> Oct 2029
    Enrollment change • Trial completion date • Trial primary completion date • Stroma
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    18d
    A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Cellcolabs Clinical LTD. | Trial completion date: Jan 2025 --> Jan 2027 | Initiation date: Oct 2023 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Stroma
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    18d
    YOBI: Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma (clinicaltrials.gov)
    P3, N=699, Active, not recruiting, Stallergenes Greer | Not yet recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Nov 2025 | Trial primary completion date: May 2024 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    18d
    Structural identification and anti-neuroinflammatory effects of a pectin-arabinoglucuronogalactan complex, AOPB-1-1, isolated from Asparagus officinalis. (PubMed, Int J Biol Macromol)
    Furthermore, its inhibitory effects on TNF-α and IL-6 levels were even better than those of minocycline. The significant anti-neuroinflammatory activity of AOPB-1-1 suggests its applicability as a therapeutic option for the treatment of Alzheimer's disease.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    IL6 expression
    19d
    Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis (clinicaltrials.gov)
    P1/2, N=9, Terminated, Enlivex Therapeutics RDO Ltd. | Trial completion date: Sep 2024 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2024; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    19d
    A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy (clinicaltrials.gov)
    P1/2, N=14, Terminated, Enlivex Therapeutics RDO Ltd. | N=72 --> 14 | Trial completion date: Dec 2024 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Apr 2024; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Tevimbra (tislelizumab) • Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    20d
    Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery. (PubMed, Open Life Sci)
    Thymosin α1 combined with XELOX is effective in improving immune function, reducing serum tumor markers, and minimizing recurrence in CRC patients after radical surgery. This combination therapy may be a promising new direction for the treatment of CRC.
    Journal • Surgery
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    capecitabine • oxaliplatin • Zadaxin (thymalfasin)
    20d
    BLOC: To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID (clinicaltrials.gov)
    P2, N=114, Active, not recruiting, Berlin Cures GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    20d
    LIFT: Life Improvement Trial (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Brigham and Women's Hospital
    New P2 trial
    26d
    TERIPET: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression (clinicaltrials.gov)
    P=N/A, N=26, Active, not recruiting, Turku University Hospital | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date
    27d
    Precision-T (PhIb component): Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P1, N=255, Recruiting, Orca Biosystems, Inc. | Trial completion date: Apr 2028 --> Jul 2026
    Trial completion date • Metastases
    |
    Orca-T
    27d
    Ursodeoxycholic Acid in C. Difficile Infection (clinicaltrials.gov)
    P=N/A, N=6, Terminated, Nottingham University Hospitals NHS Trust | N=30 --> 6 | Trial completion date: Jun 2024 --> Dec 2023 | Recruiting --> Terminated; Slow recruitment
    Enrollment change • Trial completion date • Trial termination
    27d
    Indole-3-Carbinol Promotes Apoptosis and Inhibits the Metastasis of Esophageal Squamous Cell Carcinoma by Downregulating the Wnt/β-Catenin Signaling Pathway. (PubMed, Nutr Cancer)
    MTT and flow cytometry were used to assess cell viability and apoptosis in EC18 and TE1 cells, while wound healing and transwell assays were used to investigate cell migration and invasion in vitro...I3C promoted ESCC apoptosis and inhibited cell migration and invasion by downregulating β-catenin, c-myc, and cyclin D1 in vitro and decreased the tumor growth in vivo; this process was reversed by LiCl treatment. In summary, I3C inhibits ESCC malignant behavior by suppressing the Wnt/β-catenin signaling pathway, thus deeming it a promising drug for ESCC treatment.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1)
    |
    MYC expression • CCND1 expression
    |
    mosedipimod (EC-18)
    27d
    Precision-T (PhIII component): Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P3, N=174, Recruiting, Orca Biosystems, Inc. | Trial completion date: Apr 2028 --> Apr 2027 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Orca-T
    29d
    Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer. (PubMed, J Transl Med)
    The use of antibiotics weakens immunotherapy efficacy in patients with advanced EGFR + NSCLC. The distribution characteristics and dynamic changes of gut microbiota and metabolites may indicate the efficacy of immunotherapy in advanced EGFR + NSCLC.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR wild-type
    1m
    A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (clinicaltrials.gov)
    P2, N=225, Suspended, Regeneron Pharmaceuticals | Recruiting --> Suspended
    Trial suspension • Combination therapy • Metastases
    |
    Libtayo (cemiplimab-rwlc) • vidutolimod (CMP-001)
    1m
    Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study (clinicaltrials.gov)
    P2, N=334, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne
    New P2 trial
    |
    hydroxychloroquine
    1m
    Mechanistic studies on the alleviation of ANIT-induced cholestatic liver injury by Polygala fallax Hemsl. polysaccharides. (PubMed, J Ethnopharmacol)
    In summary, this study showed that PFPs improved intrahepatic cholestasis and alleviated liver damage through the modulation of primary bile acid production, Control of protein expression related to bile secretion or transportation, decrease in inflammatory reactions, and inhibition of oxidative pressure. As a result, PFPs might offer a hopeful ethnic dietary approach for managing intrahepatic cholestasis.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    1m
    Minocycline induced apoptosis and suppressed expression of matrix metalloproteinases 2 and 9 in the breast cancer MCF-7 cells. (PubMed, Mol Biol Rep)
    These findings further confirmed the anticancer effect of minocycline and highlighted that minocycline maybe considered as potential therapeutic agent for breast cancer treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • ANXA5 (Annexin A5)
    |
    BCL2 expression
    |
    minocycline
    1m
    Anti-inflammatory and anti-rheumatic effects of Phoenix dactylifera L. (date palm) seed by controlling cytokines and inhibiting JAK1/STAT3 pathway on CFA-induced arthritis rat and its phytochemical profiling. (PubMed, J Ethnopharmacol)
    The PDS extracts especially the non-polar extract showed significant anti-inflammatory and anti-oxidative properties in the CFA-induced arthritis rat model. PDS might be used to produce RA medicines.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta) • IL22 (Interleukin 22)
    |
    chlorogenic acid
    1m
    Protective effects of sugarcane polyphenol against UV-B-induced photoaging in Balb/c mouse skin: Antioxidant, anti-inflammatory, and anti-glycosylation Effects. (PubMed, J Food Sci)
    Chlorogenic acid was determined to be the primary component of SP by using high-performance liquid chromatography-mass spectrometry...PRACTICAL APPLICATION: This study can provide a scientific basis for the practical application of sugarcane polyphenols. We expect that sugarcane polyphenols can be used in food and beverage products to provide flavor while combating skin aging.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CAT (Catalase)
    |
    chlorogenic acid
    1m
    OGFT001-001: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P1, N=186, Recruiting, Orca Biosystems, Inc. | Trial completion date: Apr 2026 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    OrcaGraft (engineered donor allograft cell therapy)
    1m
    Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne (clinicaltrials.gov)
    P1/2, N=386, Recruiting, Sanofi Pasteur, a Sanofi Company | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Williams Cancer Foundation | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Mar 2025
    Enrollment closed • Trial completion date • Metastases